Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

NCT07734415 · tracked via the Priya Life Science Canada tracker

Sponsor

Inmagene LLC

Phase

Phase 2

Started

2026-06-05

Last updated

2026-07-29

Condition(s) studied

Atopic DermatitisAtopic Dermatitis EczemaEczema

Investigational drug(s) / intervention(s)

IMG-007 →

IMG-007: Participants will receive IMG-007 subcutaneously.

Study summary

The purpose of this study is to evaluate the safety and efficacy of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis (AD)

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203

Primary outcome measure(s)

Evaluate the safety of long-term treatment with IMG-007 in participants with moderate-to-severe atopic dermatitis — Baseline, Week 44
Incidence and severity of TEAEs, including treatment-emergent SAEs, AESIs, and AEs leading to discontinuation

Trial sites (23)

Facility	City	Region
Inmagene Site 1	Lancaster	California
Inmagene Site 23	Los Angeles	California
Inmagene Site 19	Ocala	Florida
Inmagene Site 4	Tampa	Florida
Inmagene Site 2	Rolling Meadows	Illinois
Inmagene Site 6	Kew Gardens	New York
Inmagene Site 21	New York	New York
Inmagene Site 11	Woodbury	New York
Inmagene Site 20	Charlotte	North Carolina
Inmagene Site 10	Fargo	North Dakota
Inmagene Site 9	Columbus	Ohio
Inmagene Site 5	Mayfield Heights	Ohio
Inmagene Site 3	Portland	Oregon
Inmagene Site 12	Anderson	South Carolina
Inmagene Site 8	Southlake	Texas
Inmagene Site 7	Burien	Washington
Inmagene Site 15	Surrey	British Columbia
Inmagene Site 22	Vancouver	British Columbia
Inmagene Site 17	Greater Sudbury	Ontario
Inmagene Site 13	Mississauga	Ontario
Inmagene Site 18	North Bay	Ontario
Inmagene Site 14	Montreal	Quebec
Inmagene Site 16	Saskatoon	Saskatchewan

More Inmagene LLC trials in Canada

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis Recruiting

Other trials for the same condition

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment Recruiting

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis Active, not recruiting

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers Recruiting

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis Active, not recruiting

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07734415 on ClinicalTrials.gov ↗ ← All trials in Canada